文献速递心脑血管急症重症综合管理与镇静镇痛

脑血管病中脑自动调节监测的影响:一项系统综述

Impact of Cerebral Autoregulation Monitoring in Cerebrovascular Disease: A Systematic Review.
PubMed 文献 · Neurocrit Care · 2022-04-05
一句话结论系统综述提示脑血管病中脑自动调节受损与不良神经结局相关,监测脑自动调节可能有助于制定个体化管理目标。

该系统综述按PRISMA指南检索Ovid Medline、PubMed和Embase数据库至2021年1月,纳入48项采用经颅多普勒、近红外光谱或颅内压监测连续评估脑自动调节的成人研究。缺血性卒中后脑自动调节受损,组织型纤溶酶原激活剂给药和成功机械取栓后一般改善;持续受损与出血转化、恶性脑水肿和需去骨瓣减压相关。大容积脑出血后双侧脑自动调节受损可持续至发病12天,尤其合并小血管病时;动脉瘤性蛛网膜下腔出血中脑自动调节受损与血管造影血管痉挛、迟发性脑缺血和6个月不良功能结局相关。作者认为监测脑自动调节可能有助于建立个体化管理目标。

要点

  • 48项研究中23项为缺血性卒中、18项为动脉瘤性蛛网膜下腔出血、5项为脑出血、2项为系统性高血压。
  • 缺血性卒中后脑自动调节受损,组织型纤溶酶原激活剂给药和成功机械取栓后一般改善。
  • 持续脑自动调节受损与出血转化、恶性脑水肿和需去骨瓣减压相关。
  • 大容积脑出血后双侧脑自动调节受损可持续至发病12天,尤其合并小血管病时。
  • 动脉瘤性蛛网膜下腔出血中脑自动调节受损与血管造影血管痉挛、迟发性脑缺血和6个月不良功能结局相关。

适用人群与场景

  • 成人(≥18岁)脑血管病患者,包括缺血性卒中、脑出血和动脉瘤性蛛网膜下腔出血,以及系统性高血压患者。
  • 纳入使用经颅多普勒、近红外光谱和颅内压监测进行连续脑自动调节监测的研究。

研究设计与关键结果

  • 系统综述按PRISMA指南检索Ovid Medline、PubMed和Embase数据库,检索时间从各数据库建库至2021年1月,筛选2799条记录后纳入48项研究。
  • 48项研究中23项为缺血性卒中、18项为动脉瘤性蛛网膜下腔出血、5项为脑出血、2项为系统性高血压。
  • 缺血性卒中后脑自动调节受损,组织型纤溶酶原激活剂给药和成功机械取栓后一般改善;持续受损与出血转化、恶性脑水肿和需去骨瓣减压相关。
  • 大容积脑出血研究描述双侧脑自动调节受损可持续至发病12天,尤其合并小血管病时。
  • 动脉瘤性蛛网膜下腔出血中脑自动调节受损与血管造影血管痉挛、迟发性脑缺血和6个月不良功能结局相关。
  • 未治疗慢性高血压患者可能在急性卒中前即出现脑自动调节受损。

证据类型、等级与局限

  • 证据类型:系统综述,纳入病例对照研究、队列观察性研究和随机临床试验。
  • 作者指出监测脑自动调节可能有助于为脑血管病患者建立个体化管理目标。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为监测脑自动调节可能有助于为脑血管病患者建立个体化管理目标。
  • 原文未据此给出具体治疗推荐。

指南或共识出处

  • 原文引用的系统综述方法学指南:系统综述和荟萃分析优先报告条目(PRISMA)指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Cerebral autoregulation (CA) prevents brain injury by maintaining a relatively constant cerebral blood flow despite fluctuations in cerebral perfusion pressure. This process is disrupted consequent to various neurologic pathologic processes, which may result in worsening neurologic outcomes. Herein, we aim to highlight evidence describing CA changes and the impact of CA monitoring in patients with cerebrovascular disease, including ischemic stroke, intracerebral hemorrhage (ICH), and aneurysmal subarachnoid hemorrhage (aSAH). The study was preformed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. English language publications were identified through a systematic literature conducted in Ovid Medline, PubMed, and Embase databases. The search spanned the dates of each database's inception through January 2021. We selected case-control studies, cohort observational studies, and randomized clinical trials for adult patients (≥ 18 years) who were monitored with continuous metrics using transcranial Doppler, near-infrared spectroscopy, and intracranial pressure monitors. Of 2799 records screened, 48 studies met the inclusion criteria. There were 23 studies on ischemic stroke, 18 studies on aSAH, 5 studies on ICH, and 2 studies on systemic hypertension. CA impairment was reported after ischemic stroke but generally improved after tissue plasminogen activator administration and successful mechanical thrombectomy. Persistent impairment in CA was associated with hemorrhagic transformation, malignant cerebral edema, and need for hemicraniectomy. Studies that investigated large ICHs described bilateral CA impairment up to 12 days from the ictus, especially in the presence of small vessel disease. In aSAH, impairment of CA was associated with angiographic vasospasm, delayed cerebral ischemia, and poor functional outcomes at 6 months. This systematic review highlights the available evidence for CA disruption during cerebrovascular diseases and its possible association with long-term neurological outcome. CA may be disrupted even before acute stroke in patients with untreated chronic hypertension. Monitoring CA may help in establishing individualized management targets in patients with cerebrovascular disease.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Al-Kawaz M, Cho SM, Gottesman RF, et al. Impact of Cerebral Autoregulation Monitoring in Cerebrovascular Disease: A Systematic Review. Neurocrit Care. 2022. PMID: 35378665. doi:10.1007/s12028-022-01484-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。